INVESTOR ALERT: Navan, Inc. (NAVN) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action – RGRD Law

SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Navan, Inc. (NASDAQ: NAVN) common stock pursuant and/or traceable to Navan’s offering documents issued in connection with Navan’s October 31, 2025 initial public offering (“IPO”), have until Friday, April 24, 2026 to seek appointment as lead plaintiff of the Navan class action lawsuit. Captioned McCown v. Navan, Inc., No. 26-cv-01550(N.D. Cal.), the Navan class action lawsuit charges Navan as well as certain of Navan’s top executives and directors and underwriters of the IPO with violations of the Securities Act of 1933.

If you suffered substantial losses and wish to serve as lead plaintiff of the

Navan

class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-navan-inc-class-action-lawsuit-navn.html

You can also contact attorney

J.C. Sanchez

of Robbins Geller by calling 800/449-4900 or via e-mail at

[email protected]

.

CASE ALLEGATIONS: Navan operates an AI-powered software platform to simplify the travel and expense experience, benefiting users, customers, and suppliers. According to the Navan class action lawsuit, on or about October 31, 2025, Navan conducted its IPO, issuing nearly 37 million shares to the public at the offering price of $25.00 per share.

The Navan class action lawsuit alleges that the IPO’s offering documents were materially false and/or misleading and/or omitted to state that Navan would increase its sales and marketing expenses by 39% just months after the IPO to sustain its revenue, Gross Booking Volume, and usage yield growth.

The Navan class action lawsuit further alleges that on December 15, 2025, Navan reported its earnings for the quarter ended October 31, 2025, and disclosed that it increased its sales and marketing expenses to nearly $95 million, a 39% increase from its $68.5 million sales and marketing expenses in the quarter ending July 31, 2025. On this news, the price of Navan stock fell nearly 12%, according to the Navan class action lawsuit.

The complaint alleges that by the commencement of the Navan class action lawsuit, the price of Navan stock has traded as low as $9.20 per share, a nearly 63% decline from the $25.00 per share IPO price.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Navan common stock pursuant and/or traceable to the IPO to seek appointment as lead plaintiff in the Navan class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Navan investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Navan shareholder class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Navan class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        [email protected]



Shareholders who lost money in Concorde International Group Ltd. (NASDAQ: CIGL) Should Contact Wolf Haldenstein Immediately

Lead Plaintiff Deadline is May 18, 2026

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP , announces that a class action lawsuit has been filed against Concorde International Group Ltd. (“Concorde” or the “Company”) (NASDAQ: CIGL) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Concorde securities between April 21, 2025, and July 14, 2025, both dates inclusive (the “Class Period”).

Investors have until May 18, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.


PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION

According to the filed complaint, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:

  • Concorde was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals;
  • insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign;
  • Concorde’s public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price; and
  • as a result of the foregoing, defendants’ positive statements about Concorde’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

                       Why Wolf Haldenstein Adler Freeman & Herz LLP?:

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

Contact:

Firm Website:
 Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.



SMR INVESTOR ALERT: NuScale Power Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Filed by RGRD Law

SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of NuScale Power Corporation (NYSE: SMR) Class A common stock between May 13, 2025 and November 6, 2025, inclusive (the “Class Period”), have until Monday, April 20, 2026 to seek appointment as lead plaintiff of the NuScale class action lawsuit. Captioned Truedson v. NuScale Power Corporation, No. 26-cv-00328 (D. Or.), the NuScale class action lawsuit charges NuScale, certain NuScale top executive officers, as well as Fluor Corporation with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

NuScale

class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-nuscale-power-class-action-lawsuit-smr.html

You can also contact attorney

J.C. Sanchez

of Robbins Geller by calling 800/449-4900 or via e-mail at

[email protected]

.

CASE ALLEGATIONS: NuScale’s core technology, the NuScale Power Module (“NPM”), is a small modular nuclear reactor designed to generate energy within a broader power plant. Prior to the start of the Class Period, NuScale entered into a global commercialization partnership with ENTRA1 Energy LLC and NuScale and its executives claimed that this critical partnership would allow NuScale to take its NPM technology from the development stage to deployment. NuScale’s reliance on ENTRA1 as an exclusive commercialization partner appeared to be validated when, on September 2, 2025, ENTRA1 and the Tennessee Valley Authority (“TVA”) jointly announced an agreement to develop power plants to provide the TVA with up to six gigawatts of new nuclear power generation.

However, the NuScale class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) ENTRA1 had never built, financed, or operated any significant projects – let alone projects in the highly technical and complicated field of nuclear power generation – during its entire operating history; (ii) NuScale had entrusted its commercialization, distribution, and deployment of its NPMs and hundreds of millions of dollars of NuScale capital to an entity that lacked any significant prior experience owning, financing, or operating nuclear energy generation facilities; (iii) the purported experience and qualifications attributed to ENTRA1 by defendants during the Class Period in fact referred to the purported experience and qualifications of the principals of the Habboush Group, a distinct entity without significant experience in the field of nuclear power generation; and (iv) as a result, NuScale’s commercialization strategy was exposed to material, undisclosed risks of failure, delays, regulatory challenges, or other negative setbacks.

The NuScale investor class action further alleges that on November 6, 2025 NuScale revealed that NuScale’s general and administrative expenses had ballooned more than 3,000% to $519 million during its third fiscal quarter, up from $17 million in the prior year period, due largely to NuScale’s payment of $495 million to ENTRA1 for its TVA agreement. As a result, NuScale’s quarterly net loss skyrocketed to $532 million, up from $46 million in the prior year period. During the corresponding conference call, analysts pressed NuScale management regarding whether ENTRA1 was sufficiently experienced to own and operate the energy generation facilities contemplated by the TVA agreement. NuScale’s CEO, defendant John L. Hopkins, further revealed during the call that the agreement between ENTRA1 and TVA contemplated as many as 72 NPMs, meaning NuScale’s milestone payments to ENTRA1 could potentially exceed more than $3 billion. On this news, the price of NuScale Class A shares declined more than 12% over a two-day trading period.

The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased NuScale Class A common stock during the Class Period to seek appointment as lead plaintiff in the NuScale class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the NuScale class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the NuScale class action lawsuit. An investor’s ability to share in any potential future recovery of the NuScale class action lawsuit is not dependent upon serving as lead plaintiff.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        [email protected]



Osisko Development Reports Fourth Quarter and Year-End 2025 Results

(All dollar amounts are expressed in Canadian dollars, unless stated otherwise)

HIGHLIGHTS

Q4 2025 (at December 31, 2025)

  • Financial: ~$422.3 million in cash and cash equivalents; sold 3,970 ounces of gold from small-scale mining activities at the Tintic Project
  • Financing: Completed a private placement financing for ~$82.5 million in gross proceeds
  • Cariboo Gold Project: Released new infill drill results from the ongoing program in the Lowhee Zone and commenced a multi-faceted surface exploration program targeting new discoveries; pre-construction activities continued to advance, including the water treatment plant, underground development waste rock storage facility, sediment control pond, site camp upgrade and other critical infrastructure
  • Corporate: Announced sale of the San Antonio Gold Project; Appointed Scott Smith as VP, Exploration

Subsequent to Q4 2025

  • Financial: Received ~$24.9 million in proceeds from a warrants exercise
  • Financing: Completed prospectus offering of common shares for ~US$143.8 million in gross proceeds
  • Cariboo Gold Project: Resumed planned site activities in accordance with a phased reopening plan following a temporary suspension due to a fatal incident that occurred on January 22, 2026; entered into a project and construction management services agreement with JDS Energy & Mining; released new infill drill results from the ongoing Lowhee Zone (aggregate total 11,025 metres, or ~80% of planned program)
  • Corporate: Completed sale of the San Antonio Gold Project; appointed Sarah Harrison as VP, Permitting & Compliance; announced the Company’s inclusion in the VanEck Junior Gold Miners ETF (GDXJ)

MONTREAL, March 27, 2026 (GLOBE NEWSWIRE) — Osisko Development Corp. (NYSE: ODV, TSXV: ODV) (“Osisko Development” or the “Company“) reports its financial and operating results for the three and twelve months ended December 31, 2025 (“Q4 2025” and “2025“, respectively).

Q4 2025 HIGHLIGHTS

Operating, Financial and Corporate Updates:

  • As of December 31, 2025, the Company had approximately $422.3 million in cash and cash equivalents. Approximately $145.8 million (US$106.4 million), inclusive of accrued interest, is outstanding under the initial draw of the US$450 million senior secured project loan credit facility (the “2025 Financing Facility“) with funds advised by Appian Capital Advisory Limited (“Appian“) for the development and construction of the Cariboo Gold Project.
  • $24.2 million in revenues (nil in Q4 2024) and $6.8 million in cost of sales (nil in Q4 2024) generated from the sale of 3,970 gold ounces from small-scale activities including heap leaching of certain tailings and stockpile material and selective mining at the Tintic Project, generating operating income of $8.7 million ($19.8 million loss in Q4 2024).
  • During the quarter, the Company released new infill drilling results from its ongoing 13,000-metre underground infill drilling program in the Lowhee Zone of its Cariboo Gold Project. An aggregate total of 5,983 metres of drilling results was released, representing approximately 44% of the total planned program.
  • On October 29, 2025, the Company completed a private placement offering of 15,409,798 common shares of the Company for aggregate gross proceeds of approximately $82.5 million comprised of:
    • LIFE Offering ($50 million): (i) 2,990,000 common shares that qualified as “flow-through shares” (“FT Shares“) within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the “Tax Act”) at a price of $6.69 per FT Share for gross proceeds of approximately $20.0 million; (ii) 1,444,000 common shares to certain eligible British Columbia resident subscribers (the “BC FT Shares“) that qualified as “flow-through shares” within the meaning of subsection 66(15) of the Tax Act at a price of $6.93 per BC FT Share for gross proceeds of approximately $10.0 million; and (iii) 4,182,000 common shares at a price of $4.78 per common share for gross proceeds of approximately $20.0 million.
    • Private Placement ($32.5 million): 6,793,798 common shares at a price of $4.78 per common share for gross proceeds of approximately $32.5 million pursuant to exemptions available under NI 45-106.
  • On November 3, 2025, the Company announced the appointment of Mr. Scott Smith as Vice President, Exploration effective November 1, 2025.
  • On November 24, 2025, the Company announced that it entered into a securities purchase agreement with Axo Copper Corp. (“Axo“) to sell its 100% interest in the San Antonio Gold Project located in Sonora State, Mexico. The transaction closed on January 27, 2026 (refer to section entitled Discontinued Operations – San Antonio Gold Project).
  • On December 8, 2025, the Company announced the launch of a fully-funded 70,000-metre exploration drilling campaign aimed at targeting new discoveries at the Cariboo Gold Project.

Cariboo Gold Project – British Columbia, Canada (100%-owned)

  • Infill Drilling Program. The ongoing 13,000-metre infill drill program within the Lowhee Zone is being undertaken as part of the Appian 2025 Financing Facility obligations, from existing underground development infrastructure.

    • The infill program is expected to provide a comprehensive data set that will inform resource modeling, mine planning and production stope design procedures and parameters. It will also support the development of a systematic approach to infill drilling for the underground mining operation.
    • In 2025, a total of 5,983 metres of drilling was released, representing ~44% of the planned program. To date, 11,025 metres of drilling have been released, representing ~80% of the planned program, with 96% of the total planned drilling completed. Assay results and associated quality assurance and quality control reviews are pending for unreleased holes. The Company anticipates completing the 13,000-metre infill drill program in the second quarter of 2026.
  • Pre-Construction Activities. The Company continues to advance pre-construction activities, including certain surface infrastructure and underground development.

    • Water treatment plant: Upgrades to the Bonanza Ledge water treatment plant are in the final stages of commissioning and the facility is anticipated to be fully operational in the second quarter of 2026.
    • Underground development: To date, approximately 2.1 kilometres of underground development has been completed from the existing Cow Portal into the Lowhee Zone, and along the main access ramp, through the Lowhee fault, towards the Cow Mountain Zone. Development progress has been below plan while encountering challenging ground conditions in and around the Lowhee fault, requiring enhanced ground support. Development rates are expected to improve as the ramp advances beyond this zone.
    • Surface infrastructure: Construction of the waste rock storage facility, the sediment control pond, early works in the mine site complex (“MSC“) area and other critical infrastructure continues.
    • Camp upgrade: The upgrade and expansion of the site camp to 266 rooms is complete and is expected to provide accommodation capacity aligned with peak construction manpower requirements for the project.
  • Exploration & Conversion Drilling Programs. In the quarter, the Company commenced a multi-faceted exploration drilling campaign across the Cariboo Gold Project and regional targets. Together with planned infill conversion drilling, up to 20 drill rigs are expected to be active at times throughout 2026, as the various programs overlap and advance, for a combined total of approximately 160,000 metres of planned drilling across all targets.

    • A total of six drill rigs are currently operating on two surface exploration programs, including three surface drill rigs targeting exploration below the current extent of the Cariboo Gold deposit to depths of up to 1,000 metres.
    • To date, approximately 6,000 metres of drilling have been completed, with assays pending. A second surface exploration program on the adjacent Proserpine regional target has also commenced and ramped up to three drill rigs, with approximately 1,500 metres completed to date.
    • Infill and conversion drilling is planned for 2026 to upgrade inferred resources to higher level confidence resource categories with potential to be converted into mineral reserves. The initial targets are within and below the current Cariboo Gold deposit.

Figure 1: Waste rock storage facility (WRSF) aerial overview.

Figure 2: Sediment control pond (SCP) spillway pipe encasement.

Figure 3: BL water treatment plant commissioning in progress.

Figure 4: Lowhee Zone ventilation raise foundation drilling.

Figure 5: Active surface exploration drill rig on Cow Mountain targeting areas below the Cariboo Gold deposit.

Tintic Project – Utah, U.S.A. (100%-owned)

  • Small-Scale Heap Leach Project and Selective Mining. In the quarter, the Company continued small-scale heap leaching of certain tailings and stockpiled material, generating sales of 1,992 ounces of gold. In addition, small-scale selective mining activities in the quarter resulted in the sale of 1,978 ounces of gold.

    • In total, these activities resulted in the sale of 6,240 gold ounces in 2025 from the cumulative processing of 22,668 metric tonnes at an average grade of 11.17 grams per tonne gold and average recoveries of approximately 80%, generating revenue of $35.5 million ($4.6 million in 2024) and cost of sales of $13.9 million ($4.8 million in 2024).
  • While management continues to evaluate options for the next steps at the Tintic Project, it is expected that limited activities beyond care and maintenance may occur on the Tintic Project from time to time.

Figure 6: Gold bar (~276 troy ounces) poured from small-scale activities at the Tintic Project (March 2026).

2026 OBJECTIVES

Activity   Expected Timing

of Completion

2
  Anticipated 

2026 Cost

1
Cariboo Gold Project        
Underground Development (including production drilling)   Q4 2026   $40.2 million
Underground infill drilling (13,000 metres)3   Q2 2026   $0.6 million
Regional surface exploration drilling   Q4 2026   $6.8 million
Mine design, processing, water management, infrastructure and other   Q4 2026   $9.9 million
Underground Infill Drilling to Convert Mineral Resources to Mineral Reserves   Q4 2026   $1.8 million
Surface (Directional) Drilling to expand Mineral Resource Estimate at depth (up to 300 metres below current Mineral Resource Estimate)   Q4 2026   $2.5 million

Note:
   
(1) The expenditures disclosed in this table include amounts approved by the Board of Directors as at March 2026. Additional expenditures will be required to complete certain of the objectives and are subject to approval by the Board of Directors.
(2) For the portion of activities to be incurred in 2026.
(3) Underground expenditure which contributes towards satisfying one of the conditions to the subsequent draw under the 2025 Financing Facility.



DISCONTINUED OPERATIONS – SAN ANTONIO GOLD PROJECT

  • On November 24, 2025, the Company entered into an agreement to sell its 100% interest in the San Antonio Gold Project located in Sonora State, Mexico, through the sale of all of the issued and outstanding equity interests of Sapuchi Minera S. de R.L. de C.V. (“Sapuchi Minera“) which held a 100% interest in the mineral concessions comprising the San Antonio Project, to Axo Copper Corp. The transaction closed on January 27, 2026.
  • At closing, the Company received 15,325,841 common shares of Axo, representing 9.99% of Axo’s outstanding shares on a non‑diluted basis. The Company is also entitled to certain contingent deferred payments in connection with the sale, as well as an anti-dilution provision whereby a qualifying financing triggers the issuance of Axo shares to the Company. Subsequent to closing, the Company received an additional 2,363,516 Axo common shares pursuant to the anti‑dilution provision triggered by a qualifying financing. In addition to the shares received, the Company is entitled to certain contingent deferred payments, including: (i) a cash payment equal to 70% of any Mexican VAT refund relating to periods ending on or before closing; (ii) US$2 million payable in cash or Axo shares upon Axo’s filing of a NI 43‑101 compliant feasibility study; and (iii) US$2 million payable in cash upon the project’s first gold pour.

SUBSEQUENT TO Q4 2025

  • On January 22, 2026, a contractor working on surface activities suffered a fatal injury following an isolated incident at the Cariboo Gold Project. The Company promptly notified appropriate authorities, and an investigation of the incident was initiated. Activities at the project site were temporarily suspended to allow for completion of an investigation. On March 2, 2026, resumption of planned site activities was announced, following the successful implementation of a phased gradual reopening plan of surface and underground activities over several preceding weeks, in coordination with and approval from the relevant regulatory authorities, and with a focus on ensuring the health and safety of all employees and contractors.
  • On February 2, 2026, the Company appointed Ms. Sarah Harrison as Vice President, Permitting and Compliance.
  • On February 3, 2026, the Company completed its previously announced (on January 26, 2026) prospectus offering of common shares of the Company, issuing an aggregate of 40,607,650 common shares at a price of US$3.54 per common share for aggregate gross proceeds of US$143.8 million ($196.2 million).
  • On February 9, 2026, the Company entered into a definitive Project and Construction Management Services Agreement with JDS Energy & Mining Inc. for the development of the Cariboo Gold Project.
  • On March 9, 2026, the Company announced receipt of approximately $24.9 million from the exercise of 5,625,031 common share purchase warrants of the Company, held by certain funds advised by Appian Capital Advisory Limited.
  • On March 16, 2026, the Company announced inclusion in the VanEck Junior Gold Miners ETF (“GDXJ“) announced on March 13, 2026, which became effective at the close of markets on March 20, 2026.
  • On March 27, 2026, Osisko Development’s Board of Directors approved certain minor administrative amendments to the Company’s omnibus equity incentive plan to facilitate plan administration. The omnibus incentive plan was last approved by shareholders on May 7, 2025. In accordance with the terms of the omnibus equity incentive plan and applicable TSX Venture Exchange policies, shareholder approval is not required for these amendments. The amended omnibus equity incentive plan remains subject to final acceptance by the TSX Venture Exchange.

2025 Year-End Disclosure Documents

The Company’s annual information form (“AIF“) for the year ended December 31, 2025, audited consolidated financial statements (the “Financial Statements“) and related management’s discussion and analysis (“MD&A“) for the three and twelve months ended December 31, 2025 have been filed with Canadian securities regulatory authorities. Osisko Development has also filed its Annual Report Form 40-F consisting of its AIF, Financial Statements and MD&A for the year ended December 31, 2025 with the U.S. Securities and Exchange Commission.

These filings are available on the Company’s website at www.osiskodev.com, on SEDAR+ (www.sedarplus.ca) and on EDGAR (www.sec.gov) under Osisko Development’s issuer profile. Hard copies of these documents are available to shareholders of the Company upon written request to the Company’s Investor Relations department, 1100, Av. des Canadiens-de-Montreal, Suite 300, Montreal, Quebec, Canada H3B 2S2 or to [email protected].

Qualified Persons

The scientific, geological and technical information contained in this news release has been reviewed and approved by Scott Smith, P. Geo., Vice President, Exploration of Osisko Development, who is considered a “qualified person” within the meaning of National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101“).

Technical Reports

Scientific and technical information relating to the Cariboo Gold Project and the 2025 Feasibility Study on the Cariboo Gold Project is supported by the technical report titled “NI 43-101 Technical Report, Feasibility Study for the Cariboo Gold Project, District of Wells, British Columbia, Canada” and dated June 11, 2025 (with an effective date of April 25, 2025) (the “Cariboo Technical Report“).

Scientific and technical information relating to the Tintic Project and the current mineral resource estimate for the Trixie deposit (the “2024 Trixie MRE“) is supported by the technical report titled “NI 43-101 Technical Report, Mineral Resource Estimate for the Trixie Deposit, Tintic Project, Utah, United States of America” and dated April 25, 2024 (with an effective date of March 14, 2024) (the “Tintic Technical Report” and, together with the Cariboo Technical Report, the “Technical Reports“).

For readers to fully understand the information in the Technical Reports, reference should be made to the full text of the Technical Reports in their entirety, including all assumptions, parameters, qualifications, limitations and methods therein. The Technical Reports are intended to be read as a whole, and sections should not be read or relied upon out of context. The Technical Reports were prepared in accordance with NI 43-101 and are available electronically on SEDAR+ (www.sedarplus.ca) and on EDGAR (www.sec.gov) under Osisko Development’s issuer profile and on the Company’s website at www.osiskodev.com.

ABOUT
OSISKO
DEVELOPMENT
CORP.

Osisko Development Corp. is a continental North American gold development company focused on past producing mining camps with district scale potential. The Company’s objective is to become an intermediate gold producer through the development of its flagship, fully permitted, 100%-owned Cariboo Gold Project, located in central British Columbia, Canada. Its project pipeline is complemented by the Tintic Project located in the historic East Tintic mining district in Utah, U.S.A., a brownfield property with significant exploration potential, extensive historical mining data, and access to established infrastructure. Osisko Development is focused on developing long-life mining assets in mining-friendly jurisdictions while maintaining a disciplined approach to capital allocation, development risk management, and mineral inventory growth.

For further information, visit our website at www.osiskodev.com or contact:

Sean Roosen Philip Rabenok
Chairman and CEO Vice President, Investor Relations
Email: [email protected] Email: [email protected]
Tel: +1 (514) 940-0685 Tel: +1 (437) 423-3644



CAUTIONARY STATEMENTS

Cautionary Statement Regarding Financing Risks

The Company’s development and exploration activities are subject to financing risks. As of the date hereof, the Company has exploration and development assets which may generate periodic revenues through test mining but has no mines in the commercial production stage that generate positive cash flows. The Company cautions that test mining at its operations could be suspended at any time. The Company’s ability to explore for and discover potential economic projects, and then to bring them into production, is highly dependent upon its ability to raise equity and debt capital in the financial markets. Any projects that the Company develops will require significant capital expenditures. To obtain such funds, the Company may sell additional securities including, but not limited to, the Company’s shares or some form of convertible security, the effect of which may result in a substantial dilution of the equity interests of the Company’s shareholders. Alternatively, the Company may also sell a part of its interest in an asset in order to raise capital. There is no assurance that the Company will be able to raise the funds required to continue its exploration programs and finance the development of any potentially economic deposit that is identified on acceptable terms or at all. The failure to obtain the necessary financing(s) could have a material adverse effect on the Company’s growth strategy, results of operations, financial condition and project scheduling.

Cautionary Statement Regarding Test Mining Not Supported by a Feasibility Study

Certain operations of the Company including prior test mining activities at the Tintic Project’s Trixie test mine, have operated without the benefit of a feasibility study including mineral reserves, demonstrating economic and technical viability, and, as a result, there may be increased uncertainty of achieving any particular level of recovery of material or the cost of such recovery. The Company cautions that historically, such projects have a much higher risk of economic and technical failure. There is no guarantee that commercial production will commence, continue as anticipated or at all or that anticipated production costs will be achieved. The failure to commence or continue production would have a material adverse impact on the Company’s ability to generate revenue and cash flow to fund operations. Failure to achieve the anticipated production costs would have a material adverse impact on the Company’s cash flow and potential profitability.

Cautionary Statement to U.S. Investors

As a foreign private issuer under U.S. securities laws that files reports under the Canada-U.S. multijurisdictional disclosure system, the Company is permitted to prepare and report information regarding mineral properties, mineralization and estimates of mineral reserves and mineral resources, including the information in its technical reports, financial statements and MD&A, in accordance with Canadian reporting requirements, which are governed by NI 43-101. As such, such information concerning mineral properties, mineralization and estimates of mineral reserves and mineral resources, including the information in its technical reports, financial statements and MD&A, is not comparable to similar information made public by most companies subject to U.S. mineral property disclosure requirements of the U.S. Securities and Exchange Commission (“SEC“).

Further to recent amendments, U.S. mineral property disclosure requirements (the “SEC Rules“) are now governed by subpart 1300 of Regulation S-K under the U.S. Securities Act. Under the SEC Rules, the SEC now recognizes estimates of “measured mineral resources”, “indicated mineral resources” and “inferred mineral resources.” In addition, the SEC has amended its definitions of “proven mineral reserves” and “probable mineral reserves” to be “substantially similar” to the corresponding standards adopted by the Canadian Institute of Mining, Metallurgy and Petroleum, adopted by the CIM Council (“CIM Standards“), which is the required definition standard adopted by NI 43-101. While the SEC will now recognize “measured mineral resources”, “indicated mineral resources” and “inferred mineral resources”, U.S. investors should not assume that any part or all of the mineralization in these categories will ever be converted into a higher category of mineral resources or into mineral reserves. Mineralization described using these terms has a greater amount of uncertainty as to its existence and feasibility than mineralization that has been characterized as reserves. Accordingly, U.S. investors are cautioned not to assume that any measured mineral resources, indicated mineral resources, or inferred mineral resources that the Company reports are or will be economically or legally mineable. Further, “inferred mineral resources” have a greater amount of uncertainty as to their existence and as to whether they can be mined legally or economically. Therefore, U.S. investors are also cautioned not to assume that all or any part of the “inferred mineral resources” exist. Under NI 43-101, estimates of inferred mineral resources may not form the basis of feasibility or pre-feasibility studies or economic studies except for preliminary economic assessments. While the above terms are “substantially similar” to CIM Standards, there are differences in the definitions under the SEC Rules and the CIM Standards. Accordingly, there is no assurance any mineral reserves or mineral resources that the Company may report as “proven mineral reserves”, “probable mineral reserves”, “measured mineral resources”, “indicated mineral resources” and “inferred mineral resources” under NI 43-101 would be the same had the Company prepared the reserve or resource estimates under the SEC Rules.

Risks related to the development of the Cariboo Gold Project

The development of a new mining operation, including the construction of processing facilities, tailings storage infrastructure, access roads, power supply and other supporting infrastructure, is a complex and costly undertaking. The Cariboo Gold Project remains in the development stage and there is no certainty that it will be brought into commercial production within anticipated timelines, at anticipated costs, or at all. The results of the Cariboo Technical Report are based on a number of assumptions, including, among others, geological interpretations, estimated mineral resources and mineral reserves, metallurgical recoveries, construction schedules, capital and operating costs, labour and equipment availability, transportation and energy costs, regulatory requirements, and projected commodity prices. These assumptions are inherently uncertain and may prove to be inaccurate.

Actual results, costs and development timelines may differ materially from those currently anticipated due to factors such as: unforeseen geological conditions; changes to mine plan optimization; equipment failures; shortages of skilled labour and contractors; increases in the cost of materials, equipment or energy; design modifications; delays related to permitting or receipt of government approvals; adverse weather or climate conditions; and community and/or Indigenous opposition. In addition, the development of mining projects often requires substantial capital expenditures, and delays or cost overruns may require the Company to seek additional financing, which may not be available on favorable terms or at all. If the Company is unable to complete construction and development of the Cariboo Gold Project on a timely and cost-effective basis, or if operating performance following commissioning is materially lower than expected, the project may fail to achieve anticipated economic results. Any such events could have a material adverse effect on the Company’s business, financial condition and results of operations.

CAUTION REGARDING FORWARD LOOKING STATEMENTS

This news release contains “forward-looking information” (within the meaning of applicable Canadian securities laws) and “forward-looking statements” (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended) (collectively, “forward-looking statements”). Such forward-looking statements, by their nature, require Osisko Development to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements. Such forward-looking statements are not guarantees of performance and are identified with words such as “may”, “will”, “would”, “could”, “expect”, “believe”, “plan”, “anticipate”, “intend”, “estimate”, “potential”, “propose”, “project”, “outlook”, “foresee”, “continue”, “objective”, “strategy”, variants of these words or the negative or comparable terminology, as well as terms usually used in the future and the conditional. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including statements pertaining to: the availability and use of proceeds of the 2025 Financing Facility (including the ability and timing to satisfy conditions precedent to subsequent draws under the 2025 Financing Facility (if at all)); continued advancement and de-risking of the Cariboo Gold Project (if at all); the ability to develop the Cariboo Gold Project; the exploration potential and prospectivity (if any) of its properties; expectations regarding the Company’s capital requirements to advance the Cariboo Gold Project to production; the ability of the Company to raise or arrange for the remaining funding required to complete the construction of the Cariboo Gold Project; the Company’s strategy and objectives relating to the Cariboo Gold Project as well as its other projects; the impact of the 2025 Financing Facility, private placement financings, prospectus offerings, or proceeds of warrant exercises on the Company and its financial position and allocation; the ability of the Company to service and repay principal related to the 2025 Financing Facility whether from the operation of Cariboo or other sources of funds; the assumptions, qualifications and limitations relating to the Cariboo Gold Project being fully permitted and the advancement of pre-construction and early works activities; the ability, progress and timing in respect of pre-construction activities at Cariboo including the 13,000-metre infill drill program, and other surface infrastructure works; the ability, progress and timing in respect of exploration and infill drilling activities planned in 2026 at the Cariboo Gold Project and on regional targets; the ability of exploration work to support new discoveries at the Cariboo Gold Project (if at all); the utility and significance of the infill drill program and its ability to inform resource modeling, mine planning and stope design procedures and parameters (if at all); the contemplated work plan and activities at the Cariboo Gold Project and the timing, scope and results thereof and associated costs thereto; the resumption and continuation of planned site activities at the Cariboo Gold Project following the January 2026 fatal incident; the anticipated timing for the Bonanza Ledge water treatment plant to become fully operational in the second quarter of 2026; expectations regarding the improvement of underground development rates as the ramp advances beyond the Lowhee fault zone; the continuation of surface exploration drilling activities and receipt of assay results; the continuation of surface infrastructure construction, including the waste rock storage facility, sediment control pond, mine site complex early works and other critical infrastructure; expectations that the expanded camp will provide accommodation capacity aligned with peak construction manpower requirements; the ability and expectations of infill conversion drilling to upgrade inferred resources to higher level confidence resource categories with potential to be converted into mineral reserves (if at all); the utility and significance of the 2026 infill drill program; the anticipated benefits (if any) of the inclusion in the GDXJ resulting in enhanced market visibility, trading liquidity and broader investor access; the duration of the Company’s inclusion in the GDXJ; any future potential rebalances and levels of exposure over which the Company has no discretion and any impacts to trading volumes as a result thereof; assumptions, qualifications and parameters underlying the Cariboo Technical Report (including, but not limited to, the mineral resources, mineral reserves, production profile, mine design and project economics); the results of the Cariboo Technical Report as an indicator of quality and robustness of the Cariboo Gold Project, as well as other considerations that are believed to be appropriate in the circumstances; the ability of the Company to achieve the estimates outlined in the Cariboo Technical Report in the timing contemplated (if at all); the ability to achieve the capital and operating costs outlined in the Cariboo Technical Report (if at all); the ability of the Company to sustain ongoing small-scale processing and mining activities at the Tintic Project (if at all); the continuation of limited activities beyond care and maintenance continuing at the Tintic Project; the significance and impact of the definitive project and construction management services agreement with JDS Energy & Mining Inc. on the development of the Cariboo Gold Project; that the Company will receive deferred consideration payable in accordance with the terms and conditions of the relevant agreements, on a basis consistent with our expectations in relation to the divestment of the San Antonio Gold Project; in the event any deferred payment is not paid to Osisko Development, it will be able to enforce its rights under the relevant agreements in a manner consistent with its expectations in relation to the divestment of the San Antonio Gold Project; the potential impact of tariffs and other trade restrictions (if any); mineral resource category conversion; the future development and operations at the Cariboo Gold Project and the Tintic Project; the results of ongoing stakeholder engagement; the capital resources available to the Company; the ability of the Company to access capital as and when required and on terms acceptable to the Company; the ability of the Company to execute its planned activities, including as a result of its ability to seek additional funding or to reduce planned expenditures; management’s perceptions of historical trends, current conditions and expected future developments; future mining activities; the ability and timing for Cariboo to reach commercial production (if at all); sustainability and environmental impacts of operations at the Company’s properties; the results (if any) of further exploration work to define and expand mineral resources; the ability of exploration work (including drilling and sampling) to accurately predict mineralization; the ability of the Company to expand mineral resources beyond current mineral resource estimates; the ability of the Company to complete its exploration and development objectives for its projects in the timing contemplated and within expected costs (if at all); the ongoing advancement of the deposits on the Company’s properties; future gold prices; the costs required to advance the Company’s properties; the ability to adapt to changes in gold prices, estimates of costs, estimates of planned exploration and development expenditures; the profitability (if at all) of the Company’s operations; regulatory framework remaining defined and understood as well as other considerations that are believed to be appropriate in the circumstances, and any other information herein that is not a historical fact may be “forward looking information”. Osisko Development considers its assumptions to be reasonable based on information currently available but cautions the reader that their assumptions regarding future events, many of which are beyond the control of Osisko Development, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect Osisko Development and its business. Such risks and uncertainties include, but are not limited to: the absence of further work stoppages or suspensions at the Cariboo Gold Project; risks relating to third-party approvals, including the issuance of permits by governments, favourable regulatory conditions and approvals, capital market conditions and the Company’s ability to access capital on terms acceptable to the Company for the contemplated exploration and development at the Company’s properties; the absence of unforeseen ground conditions or other geological challenges; the ability to continue current operations and exploration; regulatory framework and presence of laws and regulations that may impose restrictions on mining; errors in management’s geological modelling; the timing and ability of the Company to obtain and maintain required approvals and permits; the results of exploration activities; the availability of necessary equipment, supplies and infrastructure; risks relating to exploration, development and mining activities; the global economic climate; fluctuations in metal and commodity prices; fluctuations in the currency markets; dilution; environmental risks; and community, non-governmental and governmental actions and the impact of stakeholder actions. Osisko Development is confident a robust consultation process was followed in relation to its received BC Mines Act and Environmental Management Act permits for the Cariboo Gold Project and continues to actively consult and engage with Indigenous nations and stakeholders. While any party may seek to have the decision related to the BC Mines Act and/or Environmental Management Act permits reviewed by the courts, the Company does not expect that such a review would, were it to occur, impact its ability to proceed with the construction and operation of the Cariboo Gold Project in accordance with the approved BC Mines Act and Environmental Management Act permits. Readers are urged to consult the disclosure provided under the heading “Risk Factors” in the Company’s annual information form for the year ended December 31, 2025 as well as the financial statements and MD&A for the year ended December 31, 2025, which have been filed on SEDAR+ (www.sedarplus.ca) under Osisko Development’s issuer profile and on the SEC’s EDGAR website (www.sec.gov), for further information regarding the risks and other factors facing the Company, its business and operations. Although the Company believes the expectations conveyed by the forward-looking statements are reasonable based on information available as of the date hereof, no assurances can be given as to future results, levels of activity and achievements. The Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by law. Forward-looking statements are not guarantees of performance and there can be no assurance that these forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/32e7a39a-2b45-4518-bf95-8793e37c0f57
https://www.globenewswire.com/NewsRoom/AttachmentNg/b61d3aee-a39f-46cc-8a72-368d2d88b7a0
https://www.globenewswire.com/NewsRoom/AttachmentNg/c9441604-6681-461f-9562-b1a3574bb9d0
https://www.globenewswire.com/NewsRoom/AttachmentNg/12848490-345b-4ccc-9cae-4ac7a8800da9
https://www.globenewswire.com/NewsRoom/AttachmentNg/467a8a89-f454-418e-bcc5-404f79550a38
https://www.globenewswire.com/NewsRoom/AttachmentNg/529fae59-f14f-4b1b-915d-3d75869a1e87



Quantum Biopharma Provides Corporate Update

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

TORONTO, March 27, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate update.

The Company announces the grant of 35,000 stock options (the “Stock Options”) to certain employees, and consultants. Each option granted vests immediately and is exercisable at a price of CA$6.50 for a period of five years from the issue date. The Stock Options and the common shares underlying the Stock Options are subject to a statutory four month and one day hold period. All Stock Options were granted in accordance with the Company’s stock option plan re-approved by shareholders at the Company’s annual general and special meeting held on May 19, 2023.

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 19.84% (as of December 31, 2025) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

Forward Looking Information

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements relating to: the closing of the Offering and the Debt Settlement; the use of proceeds from the Offering; and the Shares issued pursuant to the Debt Settlement, and potential issuance of Shares and Debenture Units.

Forward-looking information in this press release is based on certain assumptions and expected future events, including but not limited to: the Company has the ability to complete additional tranches of the Offering and the Debt Settlement.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: risks relating to the Company’s business and operations generally; and the reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Contacts:

Quantum BioPharma Ltd.

Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: [email protected]
Telephone: (833) 571-1811



Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

DALLAS–(BUSINESS WIRE)–
Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern” or the “Company”), an AI‑driven, clinical‑stage oncology company leveraging its proprietary RADR® platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third‑party website.

The third‑party article incorrectly claimed that Panna Sharma has stepped down as President and Chief Executive Officer of Lantern. This claim is false, entirely without basis, and appears designed to mislead investors. No such communication has been issued by the Company or its Board of Directors.

Mr. Sharma continues to serve as President, Chief Executive Officer, and a Director of Lantern, and remains fully engaged in leading the Company’s strategy, operations, and portfolio of AI‑driven oncology programs. He has no intention to step down from his roles with Lantern and he has not been requested to do so. As previously announced on March 23, 2026, Mr. Sharma will lead Lantern’s upcoming webcast to discuss fourth quarter and fiscal year 2025 operating and financial results on Monday, March 30, 2026, at 4:30 p.m. Eastern Time.

Neither Lantern nor its Board of Directors has approved or planned any CEO change. Any report suggesting otherwise is without merit.

Donald Jeff Keyser, Chairman of Lantern’s Board of Directors, stated: “The Board has full confidence in Panna Sharma’s leadership. Under his direction, Lantern continues to advance a robust clinical pipeline, including the recently cleared IND for Starlight Therapeutics’ planned Phase 1 pediatric CNS cancer trial of STAR-001 and the continued expansion of the Company’s AI‑driven drug development capabilities. We are disturbed by what appears to be a deliberate third‑party attempt to mislead investors and the market, and will pursue immediate corrective actions.”

Lantern cautions investors and other stakeholders to be vigilant against potential third‑party attempts to manipulate Lantern’s stock price through the dissemination of false or misleading information. Investors are encouraged to rely solely on Lantern’s official communications, including filings with the U.S. Securities and Exchange Commission and press releases available on the Company’s investor relations website.

The Company is actively investigating the origin and dissemination of today’s fabricated third‑party article, including any coordinated trading activity surrounding its publication. Lantern intends to pursue all available legal remedies and is considering referring this matter to the appropriate regulatory authorities.

Details for Q4 and Fiscal Year 2025 Webcast

As previously disclosed, Lantern will host a webcast to discuss its fourth quarter and fiscal year 2025 operating and financial results on Monday, March 30, 2026, at 4:30 p.m. Eastern Time. Mr. Sharma will lead the discussion and management intends to review results for the period ended December 31, 2025, and provide updates on key clinical programs and the continued evolution of the RADR® AI platform.

Additional details, including webcast access information and a replay of the webcast, will be available on the Events & Presentations section of Lantern’s investor relations website.

About Lantern Pharma

Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical‑stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and outcomes of oncology drug development. Lantern’s RADR® platform analyzes extensive genomic and drug response data to identify biomarkers that predict patient response, enabling more efficient and targeted clinical trials. For more information, visit www.lanternpharma.com.

Investor Relations Contact:

Lantern Pharma Inc.

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Technology Genetics Other Technology Clinical Trials Biotechnology Health Pharmaceutical Artificial Intelligence Oncology

MEDIA:

Logo
Logo

Kolibri Global Energy Inc. Announces Director Nominees for Upcoming Shareholder Meeting

Kolibri Global Energy Inc. Announces Director Nominees for Upcoming Shareholder Meeting

THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Kolibri Global Energy Inc. (theCompany orKolibri) (TSX: KEI, NASDAQ: KGEI) todayannounces that, following thoughtful consideration, the board of directors of Kolibri, or the Board, have resolved to nominate the individuals proposed by Tetragon Partners UK LLP for election to the Board by the shareholders of the Company at the Company’s upcoming annual general meeting of shareholders, or the Meeting, which is expected to be held on May 4, 2026. The management nominees in respect of the Meeting will be existing directors David Neuhauser and Wolf Regener (CEO), as well as Glen Brown, Lee Canaan and Murray Grigg.

Current directors Evan Templeton (Chairman), Douglas Urch, and Leslie O’Connor will not stand for re-election at the Meeting. The Company sincerely thanks them for their substantial contributions to its success during their tenures and wishes them continued success in their future endeavors. Mr. Templeton has committed to assisting the Board with transitional matters as necessary over the course of the coming months.

The Company looks forward to welcoming Glen Brown, Lee Canaan and Murray Grigg to the Board and working together to advance the Company’s strategic objectives.

Additional details regarding the management nominees will be set out in the Company’s management information circular to be mailed to shareholders in connection with the Meeting in the coming weeks. A copy of the management information circular will be available under the Company’s SEDAR+ profile at www.sedarplus.ca.

About Kolibri Global Energy Inc.

Kolibri Global Energy Inc. is a North American energy company focused on finding and exploiting energy projects in oil and gas. Through various subsidiaries, the Company owns and operates energy properties in the United States. The Company continues to utilize its technical and operational expertise to identify and acquire additional projects in oil and gas. The Company’s shares are traded on the Toronto Stock Exchange under the stock symbol KEI and on the NASDAQ under the stock symbol KGEI.

Caution Regarding Forward-Looking Information

Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws and “forward-looking statements” within the meaning of United States securities laws (collectively, “forward looking information”), including statements regarding the expected timing of the Meeting and the election of the proposed directors at the Meeting.

Forward-looking information is based on plans and estimates of management and interpretations of data by the Company’s technical team at the date the data is provided and is subject to several factors and assumptions of management, including that the Company will hold the Meeting when anticipated and that the proposed directors will be elected by shareholders at the Meeting.

Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that the Company will be unable to hold the Meeting when anticipated, or at all, that the proposed directors will not be elected by shareholders at the Meeting, and the other risks and uncertainties applicable to exploration and development activities and the Company’s business as set forth in the Company’s management discussion and analysis and its annual information form, both of which are available for viewing under the Company’s profile at www.sedarplus.ca , any of which could result in delays, cessation in planned work or loss of one or more concessions and have an adverse effect on the Company and its financial condition. The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.

For further information, contact:

Wolf E. Regener +1 (805) 484-3613

Email: [email protected]

Website: www.kolibrienergy.com

KEYWORDS: California Ireland United States United Kingdom Canada North America Europe

INDUSTRY KEYWORDS: Oil/Gas Energy

MEDIA:

Logo
Logo

Fusion Fuel Highlights Royal Uranium’s 2% NSR on Two Mineral Claims held by the Shea Creek Joint Venture, One of Canada’s Largest Undeveloped Uranium Projects in the Athabasca Basin

  • Part of a 16-uranium-royalty portfolio across the Athabasca Basin, Newfoundland, Colombia, and Argentina

Dublin, March 27, 2026 (GLOBE NEWSWIRE) — Fusion Fuel Green PLC (Nasdaq: HTOO) (“Fusion Fuel” or the “Company”), a leading provider of full-service energy engineering, advisory, and utility solutions, today highlighted information about its anticipated 2.0% Net Smelter Return (the “NSR”) royalty on two mineral claims – MC00040006 and MC0004007 – within a larger set of mineral claims held by the Shea Creek Joint Venture. The NSR is part of a portfolio of royalty rights that the Company anticipates will be acquired upon the closing of its previously announced agreement with Royal Uranium Inc. (“Royal Uranium”).

The Shea Creek Joint Venture, in the Western Athabasca Basin area of northern Saskatchewan, Canada, is operated by Orano Canada Inc., a subsidiary of French state-majority-owned nuclear fuel cycle company Orano SA, in a joint venture with Uranium Energy Corp. (“UEC”), benefiting from strong government-backed support and long-term demand driven by France’s nuclear energy program. The Western Athabasca Basin has attracted investment from some of the world’s largest nuclear energy companies and is believed to have strong expansion potential.

The Shea Creek Joint Venture discovered four deposits — Kianna, Anne, Collette, and 58B — within mineral claim S-104638.1 The mineral resource estimates below describe these four deposits. Note that the NSR royalty described in this release does not attach to claim S-104638 and will not entitle the holder of the NSR to any compensation related to production therefrom. UEC has indicated that expansion potential remains very high, with 278,889 meters of drilling across 563 drill holes completed since 1992.1

UEC’s 2022 Technical Support’s 2022 mineral resource estimate for the four deposits at a cut-off grade of 0.30% U3O8 total1:

  • 67.57 million pounds U₃O₈ indicated (2,056,000 tonnes grading 1.49% U₃O₈)
  • 28.06 million pounds U₃O₈ inferred (1,254,000 tonnes grading 1.02% U₃O₈)

The NSR is one of 16 uranium royalty interests anticipated to be acquired as part of the Royal Uranium transaction with assets located across the Athabasca Basin, Newfoundland, Colombia, and Argentina.

Global uranium demand is forecast to reach 397 million pounds by 2040 — a 118% increase from 2025 levels — while supply is projected to grow only 14%, creating an estimated annual deficit of approximately 197 million pounds by 2040.2

This gap cannot be closed by existing producers alone. Development-stage resources, such as those in the Western Athabasca Basin, will be essential to meeting demand. Additionally, the Kazatomprom Group, the world’s largest uranium producer, publicly flagged sulfuric acid shortages and construction delays during 2023–2025 that constrained planned production increases, contributing to a tighter-than-expected Western supply outlook over that period and increasing the geopolitical premium on Americas-based assets such as those in Saskatchewan.

“Shea Creek contains one of the largest undeveloped uranium resources in Canada, operated by two of the industry’s most experienced names. Through our anticipated acquisition of Royal Uranium, the holder of a 2.0% NSR royalty on mineral claims MC00004006 and MC00004007, we anticipate providing Fusion Fuel with a share of value generated from any deposits that may be discovered within those two claims without additional capital spend,” stated JP Backwell, Fusion Fuel CEO.

Background On Royal Uranium Transaction

On February 18, 2026, Fusion Fuel announced that it had entered into a definitive share exchange agreement (“Share Exchange Agreement”) to acquire a controlling interest in Royal Uranium, a private royalty company holding a portfolio of 16 royalties across the Americas. The proposed transaction is intended to provide Fusion Fuel with exposure to energy commodity royalties from certain assets, particularly uranium and natural gas deposits, through a capital-efficient royalty portfolio.

ABOUT FUSION FUEL GREEN PLC

Fusion Fuel Green PLC (NASDAQ: HTOO) provides integrated energy engineering, distribution, and green hydrogen solutions through its Al Shola Gas, BrightHy Solutions, and BioSteam Energy platforms. With operations spanning LPG supply to hydrogen and bio-steam solutions, the Company supports decarbonization across industrial, residential, and commercial sectors. For more information, please visit www.fusion-fuel.eu.

ABOUT ROYAL URANIUM INC.

Royal Uranium is a private energy royalty entity holding a portfolio of tier one high-quality uranium and natural gas royalties across premier mining jurisdictions in the Americas, operated by experienced industry partners. The portfolio is designed to provide long-duration exposure to commodity price upside while minimizing operating risk through the royalty model. For more information, please visit www.royaluranium.com.

FORWARD-LOOKING STATEMENTS

This press release and the statements contained herein include “forward-looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. In some cases, you can identify these statements because they contain words such as “may,” “will,” “believes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “should,” “seeks,” “future,” “continue,” “plan,” “target,” “predict,” “potential,” or the negative of such terms, or other comparable terminology that concern the Company’s expectations, strategy, plans, or intentions. Forward-looking statements relating to expectations about future results or events are based upon information available to the Company as of today’s date and are not guarantees of the future performance of the Company, and actual results may vary materially from the results and expectations discussed. Such forward-looking statements include, but are not limited to, statements regarding the Company’s planned acquisition of a controlling interest in Royal Uranium and its expectation to gain royalty exposure to uranium exploration activity across certain projects without additional cost to itself or the royalty holder, and statements regarding planned exploration activities at certain uranium projects. The Company’s expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the ability of the parties to the Share Exchange Agreement to complete the transaction, the Company’s ability to integrate Royal Uranium’s assets into its business, the ability of the parties to obtain Irish regulatory approval and any other required third-party consents and approvals in connection with the transaction, obtain the approval of the Company’s shareholders, and to meet all other closing conditions; the realization of revenues from the assets of Royal Uranium, including its uranium and natural gas royalties, which may depend on, among other things, the commercial development of uranium and natural gas deposits, the receipt and maintenance of exploration, mining, and environmental permits and approvals by the operators of the underlying properties, regulatory approval, and market demand for uranium and natural gas as sources of energy; volatility in uranium and natural gas commodity prices, which directly affect the potential value of NSR and other royalty interests; the risk that operators of royalty-bearing properties may delay, suspend, or abandon exploration or development activities due to insufficient funding, unfavorable economic conditions, technical challenges, or regulatory obstacles; the possibility that exploration activities, including those authorized under recently obtained permits, may not result in the discovery of commercially viable mineral deposits or hydrocarbon reserves; the dependence of the Company on third-party operators over whom it has no operational control, including decisions regarding the pace, scope, and method of exploration and development; the risk that changes in mining, environmental, or energy laws and regulations in the jurisdictions where the royalty assets are located, including Canada, Colombia, and Argentina, which may adversely affect the feasibility or economics of the underlying projects; political, economic, and social risks associated with operating in foreign jurisdictions, including currency controls, expropriation, nationalization, and changes in fiscal regimes; the risk that royalty agreements may be subject to disputes regarding their scope, enforceability, or the calculation of permitted deductions from gross revenues; competition from existing or new offerings that may emerge; impacts from strategic changes to the Company’s business on net sales, revenues, income from continuing operations, or other results of operations; the Company’s ability to obtain sufficient funding to maintain operations and develop additional services and offerings; and the risks and uncertainties described under Item 3. “Key Information – D. Risk Factors” and elsewhere in the Company’s Annual Report on Form 20-F filed with the SEC on May 9, 2025 (the “Annual Report”), and other filings with the SEC. Should any of these risks or uncertainties materialize, or should the underlying assumptions about the Company’s business and the commercial markets in which the Company operates prove incorrect, actual results may vary materially from those described as anticipated, estimated or expected in the Annual Report. All subsequent written and oral forward-looking statements concerning the Company or other matters and attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. The Company does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof, except as required by law.

Investor Relations Contact

[email protected]

www.fusion-fuel.eu


1 2022 Technical Report on the Shea Creek Project, Saskatchewan,” effective October 31, 2022, filed by Uranium Energy Corp. with the U.S. Securities and Exchange Commission (“SEC”) on January 11, 2023. Mineral resources are not mineral reserves and do not have demonstrated economic viability.
2 “Uranium’s Tale of Two Markets” (December 15, 2025), https://sprott.com/insights/uranium-s-tale-of-two-markets/.



Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025

Product Development Highlights:

  • Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression and despair and in post-traumatic stress disorder (PTSD)
  • Identified neuroplastogen candidates with potential to promote brain-derived neurotrophic factor (BDNF) signaling, an established therapeutic target for neurodegenerative disease

Corporate and Business Development Highlights:

  • Announced the withdrawal of the Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric’s issued U.S. Patent No. 12,138,276, which appears relevant to the bretisilocin (GM-2505) molecule acquired by AbbVie, Inc.
  • Continued to strengthen Enveric’s expansive IP portfolio directed to molecules intended to provide non-hallucinogenic treatment options. Multiple patents and notices of allowance were issued for its EVM301 Series, including a novel family of molecules including melatonin receptor-targeting compounds, and for its EVM401 Series

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today provided a corporate update following the filing of its 10-K on Friday, March 27, 2026, which reported financial results for the fourth quarter and year ended December 31, 2025.

CEO Commentary:

“The year 2025 was a year of important scientific progress for Enveric as we further strengthened the mechanistic rationale for our lead candidate, EB-003, a non-hallucinogenic neuroplastogen, being developed for the treatment of underserved mental health conditions,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “Our research team has continued to produce novel data, confirming EB-003’s dual-mechanism of action and its ability to promote neuroplasticity without hallucinogenic effects in animal models. We are now in the process of completing IND-supporting studies in preparation for submitting an IND application to the FDA, a key milestone that offers the potential to generate value for our stockholders and potentially deliver much-needed innovation to patients with severe and difficult to treat mental health disorders.”

Dr. Tucker added: “Our excitement around EB-003 has been further amplified by recent, independent academic research that has helped to provide additional mechanistic clarity for the field. Researchers have shown intracellular pathways downstream of 5-HT2A in the experimental models, with signal pathways potentially mediating antidepressant- and anxiolytic-like effects, distinct from pathways resulting in hallucinations. These findings from independent researchers are consistent with our strategy of designing non-hallucinogenic neuroplastogens intended to deliver therapeutic benefit without the safety, monitoring, and scalability constraints associated with psychedelic compounds.

“Also in 2025, we were gratified to see positive results from our decision to take a firm stance to defend our intellectual property and protect our discoveries. A Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals, and ultimately withdrawn by AbbVie, Inc., underscored the significance and breadth of our intellectual property footprint in the field. We believe that our patent portfolio will continue to generate value for our stockholders and support our efforts towards developing novel therapeutics to benefit patients with mental health conditions.”

Dr. Tucker concluded: “In 2026, we are working towards a streamlined IND application for EB-003 in preparation of the initiation of a first-in-human Phase 1 clinical trial. With the dual mechanism of action that engages both 5-HT2A and 5-HT1B receptors, we are optimistic that our research has the potential to profoundly impact mental health disease where innovation has been lacking for decades.”

FOURTH QUARTER, YEAR END, AND RECENT UPDATES

Corporate, Product and Business Development Highlights:

EB-003 Development:

  • Received FDA response allowing for streamlined plans for EB-003 IND submission

  • Successfully completed pre-IND dose range finding studies for EB-003 establishing maximum tolerated dose, supporting progression of EB-003 toward IND-enabling studies and first-in-human clinical trials

  • Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in a preclinical model of severe chronic depression and despair

  • Announced positive results in treatment in preclinical, exposure-based therapeutic model for post-traumatic stress disorder (PTSD) showing significantly decreased context-induced freezing behavior one-hour post-dose of EB-003

  • Achieved key manufacturing milestones in the chemistry, manufacturing, and controls (CMC) development of EB-003, key steps in scaling production and preparing the drug for required regulatory activities

Discovery:

  • Identified neuroplastogen candidates with potential to promote BDNF signaling, an established therapeutic target for neurodegenerative disease

  • Announced publication of two peer-reviewed articles highlighting novel bioproduction methods for neuropsychiatric drug discovery. Research published in ACS Chemical Biology and BioDesign Research describes new approaches for producing tryptamine and MDMA-derived compounds

Intellectual Property:

  • Vigorously defended intellectual property portfolio, highlighted by withdrawal of the Post-Grant Review (PGR) petition, which had been filed by Gilgamesh Pharmaceuticals pertaining to patents that appear relevant to the bretisilocin (GM-2505) molecule, which was acquired by AbbVie, Inc. in $1.2 billion deal

  • Continued to strengthen expansive IP portfolio and the pipeline of opportunities, receiving multiple patents and notices of allowance

    • Strengthened IP support for the EVM301 Series of compounds with multiple notices of allowance and U.S. patent issuances

    • Unveiled EVM401 Series of compounds in 2025 with four issued U.S. Patents, two of which issued in Q4 alone, for potential next-generation, non-hallucinogenic mescaline derivatives

Corporate & Financial:

  • Executed two licensing agreements with Restoration Biologics LLC, a biotechnology company focused on the treatment of joint disease for cannabinoid-COX-2 conjugate compounds, for pharmaceutical and potential non-pharmaceutical applications

  • Expanded collaboration with TOTEC Pharma LLC, a drug company focused on the development of topical cannabinoid pharmaceutical products, through a trademark license

  • Relocated corporate headquarters to Cambridge, MA to leverage the Greater Boston biotech hub’s scientific and financial ecosystem

  • During the fourth quarter of 2025, the Company raised at total of $4.9 million from a warrant inducement and an at-the-market offering. Total gross proceeds raised during fiscal year 2025 was $12.2 million

  • Completed a reverse stock split of its common stock on October 28, 2025, at a ratio of 1 post-split share for every 12 pre-split shares

FOURTH QUARTER & YEAR END FINANCIAL RESULTS

Net loss attributable to stockholders was $4.0 million for the fourth quarter ended December 31, 2025, including $0.3 million in net non-cash expense, with a basic and diluted loss per share of $6.12, as compared to a net loss of $3.2 million, including $1.0 million in net non-cash income, with a basic and diluted loss per share of $58.06 for the quarter ended December 31, 2024. The Company had cash-on-hand of $4.7 million for the quarter ended December 31, 2025. For the year ended December 31, 2025, the Company raised gross proceeds, through offerings, of $12.2 million.

Subsequent Events

In January 2026, the Company raised gross proceeds of approximately $1.5 million from a registered direct offering and, in February 2026, raised gross proceeds of approximately $1.45 million from an at-the-market offering.

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT₂A and 5-HT₁B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.

For more information, please visit www.enveric.com.

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposes,” “budgets,” “explores,” “schedules,” “seeks,” “sees,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.

A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations

Tiberend Strategic Advisors, Inc.

David Irish

(231) 632-0002

[email protected]

Media Relations

Tiberend Strategic Advisors, Inc.

Casey McDonald

(646) 577-8520

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Mental Health Research Neurology Biotechnology Health Pharmaceutical General Health Other Science Science

MEDIA:

Logo
Logo

Case IH Celebrates American Farmers At The White House

  • The Case IH Heartland Magnum tractor was featured on the South Lawn a
    s a symbol of the enduring spirit of the American farmer
  • Visitors can view the tractor at the USDA People’s Garden in Washington, D.C.

Racine, March 27, 2026 

Case IH proudly represented American farmers at the White House, bringing an enduring symbol of the industry’s strength and legacy to the nation’s capital.

Displayed on the South Lawn during a presidential “Celebration of Agriculture” event, the Case IH Heartland Magnum™ tractor stood as a tribute to the farmers who power American agriculture and to the generations of manufacturing expertise rooted in Racine, Wisconsin.

For almost four decades, the Case IH Magnum tractor has been one of the most iconic machines in modern agriculture, proudly built in the United States and trusted by farmers around the world to deliver productivity and performance season after season.

The Heartland Magnum featured at the White House reflects that legacy. Featuring a patriotic red, white and blue design, the one-of-a-kind tractor underscores agriculture’s connection to America’s identity and Case IH’s fundamental role in forging modern agriculture. The brand traces its roots back to 1842 when the company first began building equipment for US farmers, and over 180 years later, it represents generations of American manufacturing expertise that stand behind farmers in the field today.

“Being part of this celebration of agriculture is a proud moment for our team and for the farmers we serve,” said Scott Harris, President, North America, CNH. “Built in Racine since 1988, the Magnum tractor reflects the strength of American manufacturing and the performance farmers depend on every day. We are committed to supporting US agriculture with world-class equipment.” 

Case IH is part of CNH, which maintains a significant manufacturing footprint in the US, with some 8,000 employees across 10 manufacturing plants nationwide. CNH continues to invest heavily in American innovation, including a $5 billion commitment through 2030 to advanced research and development, precision technology and investment in US manufacturing.

Following the presidential event, the Heartland Magnum tractor will be moved to the USDA People’s Garden, where it will remain on display for visitors to see.

As farmers prepare for the 2026 growing season, Case IH remains focused on serving farmers by delivering the equipment and technology that help them operate efficiently and productively, continuing a legacy carried forward in fields across America.


Case IH is a global leader in agricultural equipment and solutions, with over 180 years of heritage and a commitment to delivering purposeful innovations that make all operations more productive, efficient and profitable. With a presence in more than 170 countries, Case IH supports professional producers through a dedicated network of experienced dealers and distributors. Case IH offers advanced equipment, integrated precision technology and dependable support— all designed to help customers maximize productivity and performance. Case IH offers a complete portfolio to optimize operations including tractors; harvesting, application and hay equipment; and tillage, planting and seeding systems.

Case IH is a brand of CNH Industrial N.V. (NYSE: CNH). Learn more at

www.caseih.com.

For more information contact:
Jessie Koerner
Director – Media Relations
United States 
Mobile: 551-265-6921 
e-mail: [email protected]  
www.caseih.com   

Attachments